The FDA has already approved one of the medications, with a decision on another expected by the end of April. 

The SGLT2 inhibitor, already approved for some high-risk heart failure patients, has now received a much wider approval. 

Waiting a few additional weeks, the agency wrote, could help limit myocarditis or pericarditis among young adults.

Researchers emphasized that the benefits of the vaccine still far outweigh the risks. 

10-year data from the ROOBY study found that there was little difference in outcomes between the two forms of heart bypass surgery. 

An estimated 1.2 million additional patients are now candidates for the company's small CardioMEMs HF monitor. 

The new analysis focused on both primary and secondary MR 12 months after TEER. 

The team's findings, one researcher said, "could eventually make a huge impact on many patients lives."

The medication, originally developed to treat celiac disease, could provide significant relief for young MIS-C patients. 

Don't give up on eating vegetables quite yet—but a new analysis in Frontiers in Nutrition does suggest they can't protect you from CVD all on their own.